4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-20-031054
CFO & Executive Vice President sold 29,113 shares at an average $73.33 ($2,134,885)
- CFO & Executive Vice President acquired 26,721 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Sharp Shalini · CFO & Executive Vice President
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-05-18 | Exercise or conversion : show line 1 in the form | +19,593 | $70.57 | $1,382,678 | 122,929 | D |
| 2020-05-18 | Sale : show line 2 in the form | −19,593 | $73.34 | $1,436,951 | 103,336 | D |
| 2020-05-18 | Sale : show line 3 in the form | −2,392 | $73.29 | $175,310 | 100,944 | D |
| 2020-05-19 | Exercise or conversion : show line 4 in the form | +3,221 | $48.43 | $155,993 | 104,165 | D |
| 2020-05-19 | Sale : show line 5 in the form | −3,221 | $73.32 | $236,164 | 100,944 | D |
| 2020-05-19 | Exercise or conversion : show line 6 in the form | +3,907 | $70.57 | $275,717 | 104,851 | D |
| 2020-05-19 | Sale : show line 7 in the form | −3,907 | $73.32 | $286,461 | 101,556 | D |
| Open-market sales · 29,113 sh · avg $73.33 · $2,134,885 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2020-05-18 | Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) | −19,593 | $70.57 | 2026-06-01 | 19,593 | 4,407 | D |
| 2020-05-19 | Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) | −3,221 | $48.43 | 2028-03-01 | 3,221 | 31,779 | D |
| 2020-05-19 | Exercise or conversion : show line 10 in the form Stock Option (Right to Buy) | −3,907 | $70.57 | 2026-06-01 | 3,907 | 500 | D |
Loading xslF345X03/doc4.xml…